{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T15:43:30Z","timestamp":1793375010315,"version":"4.5.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2018,11,27]],"date-time":"2018-11-27T00:00:00Z","timestamp":1543276800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2018,11,27]],"date-time":"2018-11-27T00:00:00Z","timestamp":1543276800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Herz"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1007\/s00059-018-4767-2","type":"journal-article","created":{"date-parts":[[2018,11,27]],"date-time":"2018-11-27T03:36:46Z","timestamp":1543289806000},"page":"594-602","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Efficacy and safety of rosuvastatin vs. atorvastatin in lowering LDL cholesterol","Wirksamkeit und Sicherheit von Rosuvastatin vs. Atorvastatin zur Senkung des LDL-Cholesterins"],"prefix":"10.1007","volume":"45","author":[{"given":"L.","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8765-4941","authenticated-orcid":false,"given":"J.","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,11,27]]},"reference":[{"key":"4767_CR1","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","volume":"376","author":"Cholesterol Treatment Trialists\u2019 (CTT) Collaboration","year":"2010","unstructured":"Cholesterol Treatment Trialists\u2019 (CTT) Collaboration (2010) Efficacy and safety of more intensive lowering of LDL cholesterol: a\u00a0meta-analysis of data from 170\u2008000 participants in 26 randomised trials. Lancet 376:1670\u20131681. \nhttps:\/\/doi.org\/10.1016\/S0140-6736(10)61350-5","journal-title":"Lancet"},{"key":"4767_CR2","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/S0140-6736(12)60367-5","volume":"380","author":"Cholesterol Treatment Trialists\u2019 (CTT) Collaborators","year":"2012","unstructured":"Cholesterol Treatment Trialists\u2019 (CTT) Collaborators (2012) The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 380:581\u2013590. \nhttps:\/\/doi.org\/10.1016\/S0140-6736(12)60367-5","journal-title":"Lancet"},{"key":"4767_CR3","doi-asserted-by":"publisher","first-page":"2889","DOI":"10.1016\/j.jacc.2013.11.002","volume":"63","author":"NJ Stone","year":"2014","unstructured":"Stone NJ, Robinson JG, Lichtenstein AH et\u00a0al (2014) 2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a\u00a0report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines. J\u00a0Am Coll Cardiol 63:2889\u20132934. \nhttps:\/\/doi.org\/10.1016\/j.jacc.2013.11.002","journal-title":"J Am Coll Cardiol"},{"key":"4767_CR4","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1093\/eurheartj\/ehr158","volume":"32","author":"\u017d Reiner","year":"2011","unstructured":"Reiner \u017d, Catapano AL, De Backer G et\u00a0al (2011) ESC\/EAS Guidelines for the management of dyslipidaemiasThe Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart\u00a0J 32:1769\u20131818. \nhttps:\/\/doi.org\/10.1093\/eurheartj\/ehr158","journal-title":"Eur Heart J"},{"key":"4767_CR5","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.cjca.2012.11.032","volume":"29","author":"TJ Anderson","year":"2013","unstructured":"Anderson TJ, Gr\u00e9goire J, Hegele RA et\u00a0al (2013) 2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol 29:151\u2013167. \nhttps:\/\/doi.org\/10.1016\/j.cjca.2012.11.032","journal-title":"Can J Cardiol"},{"key":"4767_CR6","unstructured":"(2010) Managing your dyslipidemia with TLC: Therapeutic Lifestyle Changes. JAOA, p eS17"},{"key":"4767_CR7","doi-asserted-by":"publisher","first-page":"234","DOI":"10.2337\/ds18-0009","volume":"31","author":"PS Jellinger","year":"2018","unstructured":"Jellinger PS (2018) American Association of Clinical Endocrinologists\/American College of Endocrinology Management of Dyslipidemia and Prevention of Cardiovascular Disease Clinical Practice Guidelines. Diabetes Spectr 31:234\u2013245. \nhttps:\/\/doi.org\/10.2337\/ds18-0009","journal-title":"Diabetes Spectr"},{"key":"4767_CR8","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.jsha.2014.09.004","volume":"27","author":"D Mahmood","year":"2015","unstructured":"Mahmood D, Jahan K, Habibullah K (2015) Primary prevention with statins in cardiovascular diseases: A Saudi Arabian perspective. J\u00a0Saudi Heart Assoc 27:179\u2013191. \nhttps:\/\/doi.org\/10.1016\/j.jsha.2014.09.004","journal-title":"J Saudi Heart Assoc"},{"key":"4767_CR9","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1111\/eci.12342","volume":"44","author":"CM Schooling","year":"2014","unstructured":"Schooling CM, Au Yeung SL, Leung GM (2014) Why do statins reduce cardiovascular disease more than other lipid modulating therapies? Eur J Clin Invest 44:1135\u20131140. \nhttps:\/\/doi.org\/10.1111\/eci.12342","journal-title":"Eur J Clin Invest"},{"key":"4767_CR10","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/S0002-9149(03)00530-7","volume":"92","author":"PH Jones","year":"2003","unstructured":"Jones PH, Davidson MH, Stein EA et\u00a0al (2003) Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol 92:152\u2013160","journal-title":"Am J Cardiol"},{"key":"4767_CR11","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.amjcard.2009.08.651","volume":"105","author":"SJ Nicholls","year":"2010","unstructured":"Nicholls SJ, Brandrup-Wognsen G, Palmer M, Barter PJ (2010) Meta-analysis of comparative efficacy of increasing dose of Atorvastatin versus Rosuvastatin versus Simvastatin on lowering levels of atherogenic lipids (from VOYAGER). Am J Cardiol 105:69\u201376. \nhttps:\/\/doi.org\/10.1016\/j.amjcard.2009.08.651","journal-title":"Am J Cardiol"},{"key":"4767_CR12","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1194\/jlr.P002816","volume":"51","author":"PJ Barter","year":"2010","unstructured":"Barter PJ, Brandrup-Wognsen G, Palmer MK, Nicholls SJ (2010) Effect of statins on HDL-C: a\u00a0complex process unrelated to changes in LDL-C: analysis of the VOYAGER Database. J\u00a0Lipid Res 51:1546\u20131553. \nhttps:\/\/doi.org\/10.1194\/jlr.P002816","journal-title":"J Lipid Res"},{"issue":"1","key":"4767_CR13","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.gheart.2014.11.004","volume":"10","author":"CM Gijsberts","year":"2015","unstructured":"Gijsberts CM, den Ruijter HM, Asselbergs FW et\u00a0al (2015) Biomarkers of Coronary Artery Disease Differ Between Asians and Caucasians in the General Population. Glob Heart 10(1):301\u2013311.e1. \nhttps:\/\/doi.org\/10.1016\/j.gheart.2014.11.004","journal-title":"Glob Heart"},{"key":"4767_CR14","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J et al (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Plos Med 6:e1000097. \nhttps:\/\/doi.org\/10.1371\/journal.pmed.1000097","journal-title":"Plos Med"},{"key":"4767_CR15","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/j.amjcard.2014.05.033","volume":"114","author":"Q Geng","year":"2014","unstructured":"Geng Q, Ren J, Song J et al (2014) Meta-analysis of the effect of statins on renal function. Am J Cardiol 114:562\u2013570. \nhttps:\/\/doi.org\/10.1016\/j.amjcard.2014.05.033","journal-title":"Am J Cardiol"},{"key":"4767_CR16","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.1253\/circj.CJ-11-0222","volume":"75","author":"T Tsutamoto","year":"2011","unstructured":"Tsutamoto T, Sakai H, Ibe K et al (2011) Effect of atorvastatin vs. rosuvastatin on cardiac sympathetic nerve activity in non-diabetic patients with dilated cardiomyopathy. Circ\u00a0J 75:2160\u20132166","journal-title":"Circ J"},{"key":"4767_CR17","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1253\/circj.CJ-10-1281","volume":"75","author":"K Saku","year":"2011","unstructured":"Saku K, Zhang B, Noda K, PATROL Trial Investigators (2011) Randomized head-to-head comparison of pitavastatin, atorvastatin, and rosuvastatin for safety and efficacy (quantity and quality of LDL): the PATROL trial. Circ\u00a0J 75:1493\u20131505","journal-title":"Circ J"},{"key":"4767_CR18","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.curtheres.2012.02.002","volume":"73","author":"T Teramoto","year":"2012","unstructured":"Teramoto T, Sawada T, Iwamoto K, Daida H (2012) Clinical efficacy and tolerability of ezetimibe in combination with atorvastatin in Japanese patients with hypercholesterolemia-ezetimibe phase IV randomized controlled trial in patients with hypercholesterolemia. Curr Ther Res Clin Exp 73:16\u201340. \nhttps:\/\/doi.org\/10.1016\/j.curtheres.2012.02.002","journal-title":"Curr Ther Res Clin Exp"},{"key":"4767_CR19","doi-asserted-by":"publisher","first-page":"159","DOI":"10.3400\/avd.AVDoa090019","volume":"2","author":"T Yamazaki","year":"2009","unstructured":"Yamazaki T, Kurabayashi M, ASTRO-1 Study Group (2009) A randomized controlled study to compare the effects of rosuvastatin 5\u202fmg and atorvastatin 10\u202fmg on the plasma lipid profile in Japanese patients with hypercholesterolemia (ASTRO-2). Ann Vasc Dis 2:159\u2013173. \nhttps:\/\/doi.org\/10.3400\/avd.AVDoa090019","journal-title":"Ann Vasc Dis"},{"key":"4767_CR20","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1007\/s12020-009-9235-6","volume":"36","author":"Y Mori","year":"2009","unstructured":"Mori Y, Kuriyama G, Tanaka T, Tajima N (2009) Usefulness of aggressive lipid-lowering therapy with rosuvastatin in hypercholesterolemic patients with concomitant type 2 diabetes. Endocrine 36:412\u2013418. \nhttps:\/\/doi.org\/10.1007\/s12020-009-9235-6","journal-title":"Endocrine"},{"key":"4767_CR21","doi-asserted-by":"publisher","first-page":"314","DOI":"10.5551\/jat.E567","volume":"15","author":"M Kurabayashi","year":"2008","unstructured":"Kurabayashi M, Yamazaki T, SUBARU Study Group (2008) Superior benefit of aggressive lipid-lowering therapy for high-risk patients using statins: the SUBARU study\u2014more hypercholesterolemic patients achieve Japan Atherosclerosis Society LDL-C goals with rosuvastatin therapy than with atorvastatin therapy. J\u00a0Atheroscler Thromb 15:314\u2013323","journal-title":"J Atheroscler Thromb"},{"key":"4767_CR22","doi-asserted-by":"publisher","first-page":"2512","DOI":"10.1253\/circj.CJ-14-0810","volume":"78","author":"H Ogawa","year":"2014","unstructured":"Ogawa H, Matsui K, Saito Y et al (2014) Differences between rosuvastatin and atorvastatin in lipid-lowering action and effect on glucose metabolism in Japanese hypercholesterolemic patients with concurrent diabetes. Lipid-lowering with highly potent statins in hyperlipidemia with type 2 diabetes patients (LISTEN) study. Circ\u00a0J 78:2512\u20132515","journal-title":"Circ J"},{"key":"4767_CR23","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1007\/s11095-008-9798-6","volume":"26","author":"H-Y Qu","year":"2009","unstructured":"Qu H\u2011Y, Xiao Y\u2011W, Jiang G\u2011H et al (2009) Effect of atorvastatin versus rosuvastatin on levels of serum lipids, inflammatory markers and adiponectin in patients with hypercholesterolemia. Pharm Res 26:958\u2013964. \nhttps:\/\/doi.org\/10.1007\/s11095-008-9798-6","journal-title":"Pharm Res"},{"key":"4767_CR24","doi-asserted-by":"publisher","first-page":"27","DOI":"10.3904\/kjim.2010.25.1.27","volume":"25","author":"J-S Park","year":"2010","unstructured":"Park J\u2011S, Kim Y\u2011J, Choi J\u2011Y et al (2010) Comparative study of low doses of rosuvastatin and atorvastatin on lipid and glycemic control in patients with metabolic syndrome and hypercholesterolemia. Korean J Intern Med 25:27\u201335. \nhttps:\/\/doi.org\/10.3904\/kjim.2010.25.1.27","journal-title":"Korean J Intern Med"},{"key":"4767_CR25","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1016\/j.amjcard.2012.01.399","volume":"109","author":"CW Lee","year":"2012","unstructured":"Lee CW, Kang S\u2011J, Ahn J\u2011M et al (2012) Comparison of effects of atorvastatin (20\u202fmg) versus rosuvastatin (10\u202fmg) therapy on mild coronary atherosclerotic plaques (from the ARTMAP trial). Am J Cardiol 109:1700\u20131704. \nhttps:\/\/doi.org\/10.1016\/j.amjcard.2012.01.399","journal-title":"Am J Cardiol"},{"key":"4767_CR26","doi-asserted-by":"publisher","first-page":"154","DOI":"10.4070\/kcj.2007.37.4.154","volume":"37","author":"KH Yun","year":"2007","unstructured":"Yun KH, Park H\u2011Y, Choi J\u2011H et al (2007) Comparison of efficacy and safety after administering high potency statin to high risk patients: rosuvastatin 10\u202fmg versus atorvastatin 20\u202fmg. Korean Circ\u00a0J 37:154. \nhttps:\/\/doi.org\/10.4070\/kcj.2007.37.4.154","journal-title":"Korean Circ J"},{"key":"4767_CR27","doi-asserted-by":"publisher","first-page":"3055","DOI":"10.1185\/030079907X242809","volume":"23","author":"J Zhu","year":"2007","unstructured":"Zhu J, Tomlinson B, Ro YM et al (2007) A randomised study comparing the efficacy and safety of rosuvastatin with atorvastatin for achieving lipid goals in clinical practice in Asian patients at high risk of cardiovascular disease (DISCOVERY-Asia study). Curr Med Res Opin 23:3055\u20133068","journal-title":"Curr Med Res Opin"},{"key":"4767_CR28","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/1755-5922.12066","volume":"32","author":"K Shioji","year":"2014","unstructured":"Shioji K, Izuhara M, Mitsuoka H et al (2014) Achievement rates of Japan Atherosclerosis Society Guidelines 2007 LDL-cholesterol goals with rosuvastatin or atorvastatin in patients who had not achieved their goal with atorvastatin. Cardiovasc Ther 32:97\u2013104. \nhttps:\/\/doi.org\/10.1111\/1755-5922.12066","journal-title":"Cardiovasc Ther"},{"key":"4767_CR29","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1177\/1074248409357922","volume":"15","author":"A-Y Her","year":"2010","unstructured":"Her A\u2011Y, Kim J\u2011Y, Kang S\u2011M et al (2010) Effects of atorvastatin 20\u202fmg, rosuvastatin 10\u202fmg, and atorvastatin\/ezetimibe 5\u202fmg\/5\u202fmg on lipoproteins and glucose metabolism. J\u00a0Cardiovasc Pharmacol Ther 15:167\u2013174. \nhttps:\/\/doi.org\/10.1177\/1074248409357922","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"4767_CR30","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1253\/circj.CJ-10-0658","volume":"75","author":"YJ Hong","year":"2011","unstructured":"Hong YJ, Jeong MH, Hachinohe D et\u00a0al (2011) Comparison of effects of rosuvastatin and atorvastatin on plaque regression in Korean patients with untreated intermediate coronary stenosis. Circ\u00a0J 75:398\u2013406","journal-title":"Circ J"},{"key":"4767_CR31","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.diabres.2015.10.013","volume":"111","author":"Y Bando","year":"2016","unstructured":"Bando Y, Toyama H, Kanehara H et al (2016) Switching from atorvastatin to rosuvastatin lowers small, dense low-density lipoprotein cholesterol levels in Japanese hypercholesterolemic patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 111:66\u201373. \nhttps:\/\/doi.org\/10.1016\/j.diabres.2015.10.013","journal-title":"Diabetes Res Clin Pract"},{"key":"4767_CR32","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1016\/j.amjcard.2012.12.037","volume":"111","author":"EP Navarese","year":"2013","unstructured":"Navarese EP, Buffon A, Andreotti F et al (2013) Meta-analysis of impact of different types and doses of Statins on new-onset diabetes mellitus. Am J Cardiol 111:1123\u20131130. \nhttps:\/\/doi.org\/10.1016\/j.amjcard.2012.12.037","journal-title":"Am J Cardiol"},{"key":"4767_CR33","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1146\/annurev.pharmtox.45.120403.095748","volume":"45","author":"JK Liao","year":"2005","unstructured":"Liao JK, Laufs U (2005) Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 45:89\u2013118. \nhttps:\/\/doi.org\/10.1146\/annurev.pharmtox.45.120403.095748","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"4767_CR34","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.atherosclerosis.2015.05.029","volume":"241","author":"BW Karlson","year":"2015","unstructured":"Karlson BW, Palmer MK, Nicholls SJ et al (2015) To what extent do high-intensity statins reduce low-density lipoprotein cholesterol in each of the four statin benefit groups identified by the 2013 American College of Cardiology\/American Heart Association guidelines? A VOYAGER meta-analysis. Atherosclerosis 241:450\u2013454. \nhttps:\/\/doi.org\/10.1016\/j.atherosclerosis.2015.05.029","journal-title":"Atherosclerosis"},{"key":"4767_CR35","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/j.amjcard.2004.01.022","volume":"93","author":"WC Roberts","year":"2004","unstructured":"Roberts WC (2004) Two more drugs for dyslipidemia. Am J Cardiol 93:809\u2013811. \nhttps:\/\/doi.org\/10.1016\/j.amjcard.2004.01.022","journal-title":"Am J Cardiol"},{"key":"4767_CR36","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1126\/science.1059344","volume":"292","author":"ES Istvan","year":"2001","unstructured":"Istvan ES, Deisenhofer J (2001) Structural mechanism for statin inhibition of HMG-CoA reductase. Science 292:1160\u20131164. \nhttps:\/\/doi.org\/10.1126\/science.1059344","journal-title":"Science"},{"key":"4767_CR37","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/S1567-5688(03)00004-7","volume":"4","author":"F McTaggart","year":"2003","unstructured":"McTaggart F (2003) Comparative pharmacology of rosuvastatin. Atheroscler Suppl 4:9\u201314","journal-title":"Atheroscler Suppl"}],"container-title":["Herz"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00059-018-4767-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00059-018-4767-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00059-018-4767-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,2]],"date-time":"2020-09-02T11:35:53Z","timestamp":1599046553000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00059-018-4767-2"}},"subtitle":["A meta-analysis of trials with East Asian populations","Metaanalyse randomisierter kontrollierter Studien in ostasiatischen Populationen"],"short-title":[],"issued":{"date-parts":[[2018,11,27]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["4767"],"URL":"https:\/\/doi.org\/10.1007\/s00059-018-4767-2","relation":{},"ISSN":["0340-9937","1615-6692"],"issn-type":[{"value":"0340-9937","type":"print"},{"value":"1615-6692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,27]]},"assertion":[{"value":"4 June 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical guidelines"}},{"value":"L.\u00a0Zhang, S.\u00a0Zhang, Y.\u00a0Yu, H.\u00a0Jiang, and J.\u00a0Ge declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}